Discover the future of inflammation treatment with CG1, our innovative polymolecular drug candidate. Designed to address the limitations of traditional biologics, CG1 offers a promising solution for patients seeking relief from inflammatory and autoimmune diseases. Learn more about how CG1 could transform the lives of patients.
Driven by a passion for innovation, Rādyx is pioneering a new era in healthcare. Our mission is to empower patients by developing groundbreaking solutions that address the complexities of chronic diseases without the burden of harmful side effects.